Assessment of Quality of Life and Outcomes in Patients With Primary Renal Cell Carcinoma Treated With SBRT

NANot yet recruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

October 31, 2021

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Renal Cell Carcinoma
Interventions
RADIATION

Stereotactic body radiotherapy

SBRT is a non-invasive treatment approach that delivers precise and highly conformal radiotherapy to the tumour with steep dose gradients that minimize exposure to the surrounding normal tissues.

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Juravinski Cancer Center

OTHER

collaborator

St. Joseph's Healthcare Hamilton

OTHER

collaborator

The Ottawa Hospital

OTHER

collaborator

Health Sciences North

OTHER

collaborator

Grand River Regional Cancer Centre

OTHER

collaborator

British Columbia Cancer Agency

OTHER

lead

Sunnybrook Health Sciences Centre

OTHER

NCT05023265 - Assessment of Quality of Life and Outcomes in Patients With Primary Renal Cell Carcinoma Treated With SBRT | Biotech Hunter | Biotech Hunter